Praxis touts top-line results from the EMBOLD study in epilepsies

Shares of Boston, USA-based CNS focused biotech Praxis Precision Medicines (Nasdaq: PRAX) closed up 4.2% at $55.38 after it shared positive top-line results for its Phase II, proof of concept study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathy (DEE) patients.

“We are thrilled to see the combination of positive efficacy and tolerability of relutrigine for SCN2A and 8A, where there are no approved treatments. When comparing to the baseline rates, patients in EMBOLD had over 2,000 fewer seizures since the beginning of the study. This kind of remarkable impact keeps us focused on advancing our programs,” said Marcio Souza, president and chief executive officer.

“Seizure freedom is the ultimate goal for patients, and we were humbled by the progress made with relutrigine during the EMBOLD study with over 30% of patients achieving this life-altering milestone,” he added.